<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.118519</article-id><article-id pub-id-type="publisher-id">ACM-44672</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210800000_90784920.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  免疫环境因子IEF在EGFR-TKIs治疗的EGFR突变阳性晚期非小细胞肺癌中预后价值研究
  The Predictive Value of Immune Environment Factors (IEF) for the Prognosis of EGFR Mutations Positive Non-Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors (EGFR-TKIs)
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杨</surname><given-names>雪</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>根利</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>玲</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>吴</surname><given-names>大鹏</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>笑荷</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>陶</surname><given-names>凤英</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>袁</surname><given-names>胜利</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>青岛大学附属青岛市立医院，山东 青岛</addr-line></aff><aff id="aff3"><addr-line>大连医科大学附属青岛大学附属青岛市立医院，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>02</day><month>08</month><year>2021</year></pub-date><volume>11</volume><issue>08</issue><fpage>3553</fpage><lpage>3561</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  目的：表皮生长因子受体–酪氨酸激酶抑制剂(epidermal growth factor receptor-tyrosine kinase inhibitors, EGFR-TKIs)厄洛替尼、吉非替尼，埃克替尼治疗前血清免疫环境因子IEF (immune environment factor)水平对晚期非小细胞肺癌(non-small cell lung cancer, NSCLC)伴有EGFR (epidermal growth factor receptor)基因突变阳性患者预后价值研究。方法：收集从2015年6月1日至2020年5月1日在青岛大学附属青岛市立医院诊断的73例接受了厄洛替尼，吉非替尼或者埃克替尼治疗的EGFR突变阳性的晚期非小细胞肺癌患者的临床资料。患者服用TKIs前1~2周完成血常规、肝肾功、凝血功能检测。利用公式IEF = Mon#(10^9/L)Neu#(10^9/L) &#215; Fibro#(10^9/L)/Lym#(10^9/L)/ALB(g/L)，其中Mon#、Neu#、Fibro#、Lym#和ALB分别代表单核细胞数目，中性粒细胞数目，纤维蛋白原数目，淋巴细胞数目和血清白蛋白水平，得出IEF值，IEF的最佳临界值将通过ROC (Receiver Operating Characteristic)曲线确定，将所有入组患者分为高IEF组和低IEF组。同时，使用COX比例风险模型(Cox Proportional-Hazards Model)分析患者预后预测因素。通过Kaplan-Meier法分析，得出高IEF组和低IEF组患者mPFS (median progression free survival)，使用Log-rank检验比较组间差异。结果：根据ROC分析结果，以IEF = 1.066 &#215; 10^17为临界值。Kaplan-Meier法分析：低IEF组的mPFS为18.0个月，而高IEF组的mPFS为8.0个月(P &lt; 0.001)。应用Cox多因素回归方法分析显示IEF (HR = 5.215, 95%CI: 2.372~11.464; P = 0.0001)，年龄，肿瘤分期，中性粒细胞计数，单核细胞计数，淋巴细胞计数是应用EGFR-TKIs治疗的EGFR突变型晚期NSCLC患者mPFS的独立影响因素，均P &lt; 0.05。同时，COX单因素分析结果显示患者的血清白蛋白，淋巴细胞计数，IEF值对患者mPFS的影响有意义，均P &lt; 0.01。结论：治疗前免疫环境因子IEF水平可作为表皮生长因子受体–酪氨酸激酶抑制剂治疗EGFR突变阳性III-IV期NSCLC患者的预后评价指标。
  Objectives: To investigate the predictive value of pretreatment immune environmental factors in serum for the prognosis of EGFR mutations positive non-small cell lung cancer (NSCLC) treated with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs). Methods: The clinical data of 73 patients with EGFR mutation positive stage IV NSCLC who were treated with erlotinib, gefitinib or icotinib from June 1, 2015 to May 1, 2020 in Qingdao Municipal Hospital were collected. The venous blood samples were taken from patients 1~2 weeks before taking TKIs, and blood routine, liver and kidney function and coagulation function were tested. According to receiver operating characteristic curve (ROC), patients were divided into high and low groups. Meanwhile, Cox proportional hazards model was used to analyze the independent prognostic factors. Kaplan Meier method was used to analyze the progression free survival (mPFs), and log rank test was used to compare the differences between the two groups. Results: According to the ROC curve, the appropriate cut-off point of IEF was 1.066 &#215; 10^17. The mPFS in the lower IEF group was longer than mPFS in the high IEF group (18.0 vs. 8.0 months, P &lt; 0.001). Cox regression analysis showed that serum albumin, lymphocyte count and IEF value had significant effect on mPFS (P &lt; 0.01). Cox multivariate regression analysis showed that IEF (HR = 5.215, 95%CI: 2.372~11.464; P = 0.0001) was significantly higher than that of control group; age, tumor stage, neutrophil count, monocyte count and lymphocyte count were independent influencing factors of mPFS (P &lt; 0.05). Conclusions: Pretreatment serum immune environment factors level can be used as a prognostic index for EGFR TKIs in patients with EGFR mutation positive stage IV NSCLC.
 
</p></abstract><kwd-group><kwd>免疫环境因子IEF，NSCLC，厄洛替尼，吉非替尼，埃克替尼，预后, Immune Environment Factors</kwd><kwd> Non-Small Cell Lung Cancer</kwd><kwd> Gefitinib</kwd><kwd> Erlotinib</kwd><kwd> Icotinib</kwd><kwd> Prognosis</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：表皮生长因子受体–酪氨酸激酶抑制剂(epidermal growth factor receptor-tyrosine kinase inhibitors, EGFR-TKIs)厄洛替尼、吉非替尼，埃克替尼治疗前血清免疫环境因子IEF (immune environment factor)水平对晚期非小细胞肺癌(non-small cell lung cancer, NSCLC)伴有EGFR (epidermal growth factor receptor)基因突变阳性患者预后价值研究。方法：收集从2015年6月1日至2020年5月1日在青岛大学附属青岛市立医院诊断的73例接受了厄洛替尼，吉非替尼或者埃克替尼治疗的EGFR突变阳性的晚期非小细胞肺癌患者的临床资料。患者服用TKIs前1~2周完成血常规、肝肾功、凝血功能检测。利用公式IEF = Mon#(10^9/L)Neu#(10^9/L) &#215; Fibro#(10^9/L)/Lym#(10^9/L)/ALB(g/L)，其中Mon#、Neu#、Fibro#、Lym#和ALB分别代表单核细胞数目，中性粒细胞数目，纤维蛋白原数目，淋巴细胞数目和血清白蛋白水平，得出IEF值，IEF的最佳临界值将通过ROC (Receiver Operating Characteristic)曲线确定，将所有入组患者分为高IEF组和低IEF组。同时，使用COX比例风险模型(Cox Proportional-Hazards Model)分析患者预后预测因素。通过Kaplan-Meier法分析，得出高IEF组和低IEF组患者mPFS (median progression free survival)，使用Log-rank检验比较组间差异。结果：根据ROC分析结果，以IEF = 1.066 &#215; 10^17为临界值。Kaplan-Meier法分析：低IEF组的mPFS为18.0个月，而高IEF组的mPFS为8.0个月(P &lt; 0.001)。应用Cox多因素回归方法分析显示IEF (HR = 5.215, 95%CI: 2.372~11.464; P = 0.0001)，年龄，肿瘤分期，中性粒细胞计数，单核细胞计数，淋巴细胞计数是应用EGFR-TKIs治疗的EGFR突变型晚期NSCLC患者mPFS的独立影响因素，均P &lt; 0.05。同时，COX单因素分析结果显示患者的血清白蛋白，淋巴细胞计数，IEF值对患者mPFS的影响有意义，均P &lt; 0.01。结论：治疗前免疫环境因子IEF水平可作为表皮生长因子受体–酪氨酸激酶抑制剂治疗EGFR突变阳性III-IV期NSCLC患者的预后评价指标。</p></sec><sec id="s2"><title>关键词</title><p>免疫环境因子IEF，NSCLC，厄洛替尼，吉非替尼，埃克替尼，预后</p></sec><sec id="s3"><title>The Predictive Value of Immune Environment Factors (IEF) for the Prognosis of EGFR Mutations Positive Non-Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors (EGFR-TKIs)<sup> </sup></title><p>Xue Yang<sup>1</sup>, Genli Liu<sup>2</sup>, Ling Li<sup>1</sup>, Dapeng Wu<sup>1</sup>, Xiaohe Wang<sup>1</sup>, Fengying Tao<sup>1</sup>, Shengli Yuan<sup>1*</sup></p><p><sup>1</sup>Department of Oncology, The Affiliated Qingdao Municipal Hospital of Qingdao University Medical College, Qingdao Shandong</p><p><sup>2</sup>Department of Oncology, The Affiliated Qingdao Municipal Hospital of Dalian Medical University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/36-1572448x5_hanspub.png?20210823083603374" /></p><p>Received: Jul. 16<sup>th</sup>, 2021; accepted: Aug. 13<sup>th</sup>, 2021; published: Aug. 20<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/36-1572448x6_hanspub.png?20210823083603374" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objectives: To investigate the predictive value of pretreatment immune environmental factors in serum for the prognosis of EGFR mutations positive non-small cell lung cancer (NSCLC) treated with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs). Methods: The clinical data of 73 patients with EGFR mutation positive stage IV NSCLC who were treated with erlotinib, gefitinib or icotinib from June 1, 2015 to May 1, 2020 in Qingdao Municipal Hospital were collected. The venous blood samples were taken from patients 1~2 weeks before taking TKIs, and blood routine, liver and kidney function and coagulation function were tested. According to receiver operating characteristic curve (ROC), patients were divided into high and low groups. Meanwhile, Cox proportional hazards model was used to analyze the independent prognostic factors. Kaplan Meier method was used to analyze the progression free survival (mPFs), and log rank test was used to compare the differences between the two groups. Results: According to the ROC curve, the appropriate cut-off point of IEF was 1.066 &#215; 10^17. The mPFS in the lower IEF group was longer than mPFS in the high IEF group (18.0 vs. 8.0 months, P &lt; 0.001). Cox regression analysis showed that serum albumin, lymphocyte count and IEF value had significant effect on mPFS (P &lt; 0.01). Cox multivariate regression analysis showed that IEF (HR = 5.215, 95%CI: 2.372~11.464; P = 0.0001) was significantly higher than that of control group; age, tumor stage, neutrophil count, monocyte count and lymphocyte count were independent influencing factors of mPFS (P &lt; 0.05). Conclusions: Pretreatment serum immune environment factors level can be used as a prognostic index for EGFR TKIs in patients with EGFR mutation positive stage IV NSCLC.</p><p>Keywords:Immune Environment Factors, Non-Small Cell Lung Cancer, Gefitinib, Erlotinib, Icotinib, Prognosis</p><disp-formula id="hanspub.44672-formula19"><graphic xlink:href="//html.hanspub.org/file/36-1572448x7_hanspub.png?20210823083603374"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/36-1572448x8_hanspub.png?20210823083603374" /> <img src="//html.hanspub.org/file/36-1572448x9_hanspub.png?20210823083603374" /></p></sec><sec id="s5"><title>1. 引言</title><p>肺癌发病率逐年升高，影响人类的寿命和生活质量，占所有癌种死亡率第一位，其中NSCLC占比约80% [<xref ref-type="bibr" rid="hanspub.44672-ref1">1</xref>]。亚洲人的表皮生长因子受体(epidermal growth factor receptor, EGFR)阳性突变率约为50%，是应用EGFR-TKIs天然优势人群。与传统化疗方案相比，EGFR-TKIs能靶向性杀伤驱动基因阳性NSCLC细胞，具有延长肿瘤患者的生存时间和提高生活质量，血液学毒性以及胃肠反应较小，不良反应可耐受，口服给药，更易通过血脑屏障等优点 [<xref ref-type="bibr" rid="hanspub.44672-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.44672-ref3">3</xref>]。但是其临床获益率也只有80%左右，少数患者不能对治疗产生有效反应 [<xref ref-type="bibr" rid="hanspub.44672-ref4">4</xref>]。临床观察，EGFR-TKIs的疗效可能与患者临床病理特征有关，因此研究能影响患者EGFR-TKIs治疗疗效的综合性临床指标有必要。NEMETH T.等人研究表明，中性粒细胞，单核细胞和淋巴细胞在肿瘤炎症中起关键作用 [<xref ref-type="bibr" rid="hanspub.44672-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.44672-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.44672-ref7">7</xref>]。纤维蛋白原反应凝血情况 [<xref ref-type="bibr" rid="hanspub.44672-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.44672-ref9">9</xref>] [<xref ref-type="bibr" rid="hanspub.44672-ref10">10</xref>]，白蛋白反应肿瘤的营养情况 [<xref ref-type="bibr" rid="hanspub.44672-ref11">11</xref>]。近年来的研究显示升高的中性粒细胞与淋巴细胞比值和降低的淋巴细胞与单核细胞比值与包括晚期NSCLC在内的多种肿瘤的不良预后相关。IEF = 中性粒细胞 * 单核细胞 * 纤维蛋白原/淋巴细胞/白蛋白，它在一定程度上可以反映机体炎症、免疫调节和营养代谢状态。同时，对于EGFR突变阳性的晚期NSCLC，体现人体营养代谢、炎症、免疫调剂状况指标IEF与EGFR突变阳性NSCLC患者预后关系目前从未有人研究。本研究旨在探索治疗前IEF水平对于EGFR突变阳性III-IV期NSCLC患者的预后预测价值。</p></sec><sec id="s6"><title>2. 资料与方法</title><p>EGFR突变的NSCLC患者。入组患者皆为一线厄洛替尼，吉非替尼或者埃克替尼治疗，给予吉非替尼250 mg po 1片/qd，埃克替尼125 mg po 1片/tid或厄洛替尼150 mg po 1片/qd。本研究获得青岛大学附属青岛市立医院伦理委员会批准，研究患者知情同意。</p><sec id="s6_1"><title>2.1. 纳入、排除标准</title><p>纳入标准：① 病理确诊为：NSCLC，并应用NGS法或者ARMS法进行检测，EGFR基因突变阳性；② 根据美国癌症联合委员会AJCC制定第八版TNM分期标准，划分为III或IV期肺癌；③ 接受一线厄洛替尼，吉非替尼或者埃克替尼治疗；④ 在厄洛替尼，吉非替尼或埃克替尼治疗前1~2周内行血常规等相关检查。</p><p>排除标准：① 存在其他原发肿瘤；② 心功能III-IV级(NYHA)，贫血，肝硬化，肾功能损伤严重；③ 厄洛替尼、吉非替尼、埃克替尼治疗前的2周内有急、慢性炎性疾病，或自身免疫性疾病，或血液病；④ 未进行规范性治疗以及相关评估；⑤ 因其他疾病或者意外导致死亡。⑥ 治疗前使用过甲强龙等激素，瑞白等升白细胞药物，白蛋白等可能影响血液检测结果的药物。</p></sec><sec id="s6_2"><title>2.2. 方法及数据收集</title><p>采集患者厄洛替尼，吉非替尼或埃克替尼治疗前1~2周内的静脉血，以及迈瑞EXC810分析仪、罗氏E601分析仪以及贝克曼5800分析仪分别用于肝肾功，肿瘤标志物以及凝血常规检测。迈瑞BC-6000分析仪检测血常规，Wright或Mary-Grinewald-Giemsa技术用于确定差值计数。将一滴血稀薄地铺在玻璃片上，风干，并用Romanowsky染色剂染色。使用分馏仪自动评估分化，手动评估形态异常的玻片。从青岛大学附属青岛市立医院瑞美系统汇总检验结果。TNM分期根据美国癌症联合委员会第7版进行分类。定义：IEF = Mon#(10^9/L) &#180; Neu#(10^9/L) &#215; Fibro#(10^9/L)/Lym#(10^9/L)/ALB(g/L)，其中Mon#、Neu#、Fibro#、Lym#和ALB分别代表单核细胞数目，中性粒细胞数目，纤维蛋白原数目，淋巴细胞数目和血清白蛋白水平。</p><p>随访：治疗后6周复查，此后每2~3个月随访1次。按照实体瘤疗效评价标准1.1 (Response Evaluation Criteria in Solid Tumors 1.1，RECIST 1.1)评价疗效。PFS为本研究主要终点，定义为从患者服用EGFR-TKIs药物的第一天开始，至疾病影像学进展或死亡或末次随访。随访截止到2020年5月1日或患者在随访期间发生死亡。</p></sec><sec id="s6_3"><title>2.3. 统计分析</title><p>为了确定本研究中的IEF的临界值，按照7:3比例将所有患者随机分组，命名为训练集和对照集。采样时间为12月。使用Youden指数确定训练集中IEF的临界点。通过ROC确定临界值。我们使用Youden指数评估了区分复发的最佳分界点 [<xref ref-type="bibr" rid="hanspub.44672-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.44672-ref13">13</xref>]。根据ROC曲线计算出Youden指数，公式如下：</p><p>Youden 指 数 = 最 大 灵 敏 度 ( 1 − 特 异 性 )</p><p>使用卡方检验评估IEF与各变量之间的关系。生存曲线使用Kaplan-Meier方法绘制，各组比较通过Log-rank检验进行。单变量Cox比例风险模型和多变量Cox比例风险模型用于确定与患者的独立预后因素。使用SPSS 25版和GraphPad Prism5.0进行软件分析。显着性定义为P &lt; 0.05，且95%置信区间(CI)，不包括1。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 临床病理特征</title><p>73例患者，临床病理特征如下：临床疗效随访截止2020年05月01日，其中73例患者发生疾病进展，5例患者死亡，68例患者存活，失访0例。73例患者中，中位mPFS 10.0个月。性别：48例(65.75%)为女性和25例(34.25%)为男性。靶向药物种类：28例(38.36%)服用吉非替尼和31例(42.46)服用埃克替尼和14例(19.18%)服用厄洛替尼。血清ALB水平：53例(72.6%) &#179; 35 g/L和20例(27.4%) &lt; 35 g/L。外周血Neu#：6例(8.22%) &#179; 6.3 &#180; 10^9/L和67例(91.78%) &lt; 6.3 &#180; 10^9/L。年龄：27例(36.99%) &lt; 65岁和46例(63.01%) &#179; 65岁。肿瘤分期：42例(57.53%)为IV期患者和31例(42.47%)为III期患者。外周血Lym#：55例(75.34%) &#179; 1.1 &#180; 10^9/L和18例(24.66%) &lt; 1.1 &#180; 10^9/L (见表1)。</p></sec><sec id="s7_2"><title>3.2. IEF最佳临界值的确定</title><p>根据治疗前血常规，肝功，肾功，凝血常规检测结果计算IEF，将IEF值和患者mPFS情况作为ROC曲线的分析值。经计算得出：IEF最佳临界值为1.066 &#215; 10^17，灵敏度、特异度分别为84%和77.1%，ROC曲线下面积为0.815 (95% CI: 0.704~0.926)。根据最佳临界值将入组患者分为高IEF组(IEF &gt; 1.066 &#215; 10^17)和低IEF组(IEF ≤ 1.066 &#215; 10^17)。</p></sec><sec id="s7_3"><title>3.3. 不同IEF组的特征</title><p>高IEF组41例和低IEF组32例。低IEF组比高IEF组患者有更好的肿瘤分期(P = 0.01)，更高的淋巴细胞计数(P = 0.007)。女性患者更倾向于有低的IEF评分(P = 0.001)，而患者的年龄、中性粒细胞计数、单核细胞计数、纤维蛋白原水平、靶向药物分类在高、低IEF组之间，差异均无统计学意义(见表1)。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Characteristics of the study population with NSCL</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >临床病理特点</th><th align="center" valign="middle" >低IEF组</th><th align="center" valign="middle" >高IEF组</th><th align="center" valign="middle"  rowspan="2"  >P value</th></tr></thead><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >N = 32 (%)</td><td align="center" valign="middle" >N = 41 (%)</td></tr><tr><td align="center" valign="middle" >性别</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.001</td></tr><tr><td align="center" valign="middle" >男</td><td align="center" valign="middle" >4 (12.5)</td><td align="center" valign="middle" >21 (51.22)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >女</td><td align="center" valign="middle" >28 (87.5)</td><td align="center" valign="middle" >20 (48.78)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >年龄(岁)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.166</td></tr><tr><td align="center" valign="middle" >&lt;65</td><td align="center" valign="middle" >23 (71.875)</td><td align="center" valign="middle" >23 (56.10)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&#179;65</td><td align="center" valign="middle" >9 (28.125)</td><td align="center" valign="middle" >18 (43.90)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >肿瘤分期</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.01</td></tr><tr><td align="center" valign="middle" >III期</td><td align="center" valign="middle" >19 (59.375)</td><td align="center" valign="middle" >12 (29.27)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >IV期</td><td align="center" valign="middle" >13 (40.625)</td><td align="center" valign="middle" >29 (70.73)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >靶向药物</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.012</td></tr><tr><td align="center" valign="middle" >厄洛替尼</td><td align="center" valign="middle" >6 (18.75)</td><td align="center" valign="middle" >8 (19.51)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >吉非替尼</td><td align="center" valign="middle" >18 (56.25)</td><td align="center" valign="middle" >10 (24.39)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >埃克替尼</td><td align="center" valign="middle" >8 (25)</td><td align="center" valign="middle" >23 (56.10)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >中性粒细胞计数(10<sup>9</sup>/L)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.588</td></tr><tr><td align="center" valign="middle" >&lt;6.3</td><td align="center" valign="middle" >30 (93.75)</td><td align="center" valign="middle" >37 (90.24)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >≥6.3</td><td align="center" valign="middle" >2 (6.25)</td><td align="center" valign="middle" >4 (9.76)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >单核细胞计数(10<sup>9</sup>/L)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.295</td></tr><tr><td align="center" valign="middle" >&lt;0.6</td><td align="center" valign="middle" >28 (87.5)</td><td align="center" valign="middle" >32 (78.05)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >≥0.6</td><td align="center" valign="middle" >4 (12.5)</td><td align="center" valign="middle" >9 (21.95)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >纤维蛋白原(g/L)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.145</td></tr><tr><td align="center" valign="middle" >&lt;3.5</td><td align="center" valign="middle" >12 (37.5)</td><td align="center" valign="middle" >9 (21.96)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >≥3.5</td><td align="center" valign="middle" >20 (62.5)</td><td align="center" valign="middle" >32 (78.04)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >血清白蛋白(g/L)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.046</td></tr><tr><td align="center" valign="middle" >&lt;35</td><td align="center" valign="middle" >5 (15.625)</td><td align="center" valign="middle" >15 (36.59)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >≥35</td><td align="center" valign="middle" >27 (84.375)</td><td align="center" valign="middle" >26 (63.41)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >淋巴细胞计数(10<sup>9</sup>/L)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.007</td></tr><tr><td align="center" valign="middle" >&lt;1.1</td><td align="center" valign="middle" >3 (9.375)</td><td align="center" valign="middle" >15 (36.59)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >≥1.1</td><td align="center" valign="middle" >29 (90.625)</td><td align="center" valign="middle" >26 (63.41)</td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>表1. NSCLC患者临床病理特征</p></sec><sec id="s7_4"><title>3.4. IEF与应用EGFR-TKIs治疗的NSCLC患者mPFS的关系</title><p>中位的随访时间为23个月(10~47个月)。低、高组患者的IEF组mPFS分别为18.0、8.0个月，高IEF组患者的mPFS比低IEF组患者更差(Log-rank P &lt; 0.01)。EGFR-TKIs治疗的低、高IEF组NSCLC患者的PFS曲线通过GraphPad Prism5.0绘制而成，mPFS组间差异通过应用Log-rank法比较(见图1)。</p><p>图1. 中位无进展生存时间</p></sec><sec id="s7_5"><title>3.5. EGFR-TKIs治疗的EGFR突变型NSCLC患者预后影响因素分析</title><p>IEF分组与患者预后的关系：COX多因素分析结果显示：外周血中性粒细胞计数(HR = 8.095, 95%CI: 2.379~27.546; P = 0.001)、年龄(HR = 0.345, 95%CI: 0.174~0.684; P = 0.002)，外周血单核细胞计数(HR = 0.304, 95%CI: 0.128~0.725; P = 0.007)、外周血淋巴细胞计数(HR = 0.361, 95%CI: 0.172~0.756; P = 0.007)、IEF (HR = 5.215, 95%CI: 2.372~27.546; P = 0.0001)是应用EGFR-TKIs治疗的EGFR突变型III-IV期NSCLC患者mPFS的独立预后因素，同时，疗前外周血中性粒细胞计数，年龄 &gt; 65岁，外周血单核细胞计数，外周血淋巴细胞计数及IEF值 &#179; 1.066 &#215; 10^17，为应用EGFR-TKIs治疗的EGFR突变型的III-IV期NSCLC患者mPFS的独立危险因素。同时，Cox单因素回归方法分析提示患者的血清白蛋白，血液淋巴细胞计数，IEF值对EGFR-TKIs治疗的EGFR突变型晚期NSCLC患者的mPFS有意义，均P &lt; 0.01 (见表2)。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Cox univariate and multivariate analysis tabl</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >临床病理特点</th><th align="center" valign="middle" ></th><th align="center" valign="middle" >单因素</th><th align="center" valign="middle" ></th><th align="center" valign="middle" ></th><th align="center" valign="middle" >多因素</th><th align="center" valign="middle" ></th></tr></thead><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >HR</td><td align="center" valign="middle" >95%CI</td><td align="center" valign="middle" >P值</td><td align="center" valign="middle" >HR</td><td align="center" valign="middle" >95%CI</td><td align="center" valign="middle" >P值</td></tr><tr><td align="center" valign="middle" >性别</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >男</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >女</td><td align="center" valign="middle" >1.936</td><td align="center" valign="middle" >1.164~3.220</td><td align="center" valign="middle" >0.011</td><td align="center" valign="middle" >0.723</td><td align="center" valign="middle" >0.305~1.714</td><td align="center" valign="middle" >0.462</td></tr><tr><td align="center" valign="middle" >年龄(岁)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&lt;65</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&#179;65</td><td align="center" valign="middle" >1.268</td><td align="center" valign="middle" >0.774~2.078</td><td align="center" valign="middle" >0.345</td><td align="center" valign="middle" >0.345</td><td align="center" valign="middle" >0.174~0.684</td><td align="center" valign="middle" >0.002</td></tr><tr><td align="center" valign="middle" >肿瘤分期</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >III期</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >IV期</td><td align="center" valign="middle" >2.051</td><td align="center" valign="middle" >1.221~3.444</td><td align="center" valign="middle" >0.007</td><td align="center" valign="middle" >2.436</td><td align="center" valign="middle" >1.178~5.039</td><td align="center" valign="middle" >0.016</td></tr><tr><td align="center" valign="middle" >靶向药物</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >埃克替尼</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >厄洛替尼</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >吉非替尼</td><td align="center" valign="middle" >1.191</td><td align="center" valign="middle" >0.843~1.684</td><td align="center" valign="middle" >0.322</td><td align="center" valign="middle" >0.652</td><td align="center" valign="middle" >0.421~1.011</td><td align="center" valign="middle" >0.652</td></tr><tr><td align="center" valign="middle" >中性粒细胞计数(10<sup>9</sup>/L)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&lt;6.3</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >≥6.3</td><td align="center" valign="middle" >2.772</td><td align="center" valign="middle" >1.156~6.646</td><td align="center" valign="middle" >0.022</td><td align="center" valign="middle" >8.095</td><td align="center" valign="middle" >2.379~27.546</td><td align="center" valign="middle" >0.001</td></tr><tr><td align="center" valign="middle" >单核细胞计数(10<sup>9</sup>/L)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&lt;0.6</td><td align="center" valign="middle" >0.642</td><td align="center" valign="middle" >0.335~1.231</td><td align="center" valign="middle" >0.182</td><td align="center" valign="middle" >0.304</td><td align="center" valign="middle" >0.128~0.725</td><td align="center" valign="middle" >0.007</td></tr><tr><td align="center" valign="middle" >≥0.6</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >纤维蛋白原(g/L)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&lt;3.5</td><td align="center" valign="middle" >0.877</td><td align="center" valign="middle" >0.522~1.473</td><td align="center" valign="middle" >0.621</td><td align="center" valign="middle" >0.448</td><td align="center" valign="middle" >0.236~0.849</td><td align="center" valign="middle" >0.014</td></tr><tr><td align="center" valign="middle" >≥3.5</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >血清白蛋白(g/L)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&lt;35</td><td align="center" valign="middle" >0.448</td><td align="center" valign="middle" >0.262~0.764</td><td align="center" valign="middle" >0.003</td><td align="center" valign="middle" >0.355</td><td align="center" valign="middle" >0.148~0.852</td><td align="center" valign="middle" >0.020</td></tr><tr><td align="center" valign="middle" >≥35</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >淋巴细胞计数(10<sup>9</sup>/L)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&lt;1.1</td><td align="center" valign="middle" >0.395</td><td align="center" valign="middle" >0.220~0.710</td><td align="center" valign="middle" >0.002</td><td align="center" valign="middle" >0.361</td><td align="center" valign="middle" >0.172~0.756</td><td align="center" valign="middle" >0.007</td></tr><tr><td align="center" valign="middle" >≥1.1</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >IEF</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&lt;1.066 &#215; 10^17</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&#179;1.066 &#215; 10^17</td><td align="center" valign="middle" >5.249</td><td align="center" valign="middle" >2.804~9.825</td><td align="center" valign="middle" >&lt;0.001</td><td align="center" valign="middle" >5.215</td><td align="center" valign="middle" >2.372~27.546</td><td align="center" valign="middle" >&lt;0.001</td></tr></tbody></table></table-wrap><p>表2. Cox单因素、多因素分析表</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>本研究回顾性分析了青岛大学附属青岛市立医院73例应用厄洛替尼、吉非替尼、埃克替尼治疗的晚期NSCLC患者的数据，COX回归分析显示治疗前血液中IEF水平，患者年龄，肿瘤分期，中性粒细胞、单核细胞和淋巴细胞计数可以影响NSCLC患者的预后。同时，免疫环境因子IEF可以预测EGFR-TKIs治疗的III-IV期EGFR突变阳性NSCLC患者靶向治疗的预后。</p><p>CHEN X.等人研究显示：炎症反应与多数癌症患者不良预后有关 [<xref ref-type="bibr" rid="hanspub.44672-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.44672-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.44672-ref16">16</xref>]。MANDALIYA H.等人研究表明，外周血中单核细胞与淋巴细胞比值，中性粒细胞与淋巴细胞比值，CRP等血液学指标与EGFR突变阳性NSCLC预后相关。本研究中使用的指标：中性粒细胞是血液循环中数量最多的白细胞，在不同阶段肿瘤的发生发展中是一把双刃剑，可以作为人体天然防御系统的一部分，同时调节适应性免疫，也可以加重肿瘤的炎性反应，释放细胞因子，重塑细胞外基质，影响肿瘤的侵袭和增殖能力。XIAO Y.等人研究显示，在肿瘤微环境中，肿瘤相关中性粒细胞(TANs)在TGF-β，IL-8，IL-6，IL-17等细胞因子的作用下可以由抗肿瘤的N1细胞极化为促肿瘤N2细胞，并通过促进血管生成，肿瘤浸润等途径，导致患者不良预后 [<xref ref-type="bibr" rid="hanspub.44672-ref17">17</xref>] [<xref ref-type="bibr" rid="hanspub.44672-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.44672-ref19">19</xref>]。此外，RAPOPORT B.L.等人研究表明，外周血中性粒细胞计数升高与患者疾病的局部控制率降低等不良临床预后相关 [<xref ref-type="bibr" rid="hanspub.44672-ref18">18</xref>]。所以中性粒细胞是肿瘤患者血象分析重要一部分。来源于单核细胞的巨噬细胞在肿瘤免疫中发挥重要作用。CHOI S.H.等研究发现，肿瘤相关巨噬细胞(TAMs)在肿瘤微环境免疫细胞中占有最大比例，在细胞因子CSF-1、IL-4、IL-10、TGF-β等的作用下，可以由抗肿瘤的M1细胞转化为M2细胞，它们通过分泌基质金属蛋白酶(MMPs)影响肿瘤微环境，并通过分泌PDGF，VEGF和转化生长因子(TGF-β)来诱导血管形成 [<xref ref-type="bibr" rid="hanspub.44672-ref20">20</xref>]，同时抑制T细胞免疫应答 [<xref ref-type="bibr" rid="hanspub.44672-ref21">21</xref>] [<xref ref-type="bibr" rid="hanspub.44672-ref22">22</xref>] [<xref ref-type="bibr" rid="hanspub.44672-ref23">23</xref>]。这可能在一定程度上解释了单核细胞对肿瘤预后的影响。淋巴细胞是人体特异性免疫重要组成部分，JOSHI K.等人研究证实，细胞毒性T细胞(CTL)可以产生穿孔素，颗粒酶等细胞因子，促使肿瘤细胞凋亡，辅助性T细胞参与激活CTL过程 [<xref ref-type="bibr" rid="hanspub.44672-ref24">24</xref>] [<xref ref-type="bibr" rid="hanspub.44672-ref25">25</xref>]。INOMATA M.等人研究表明，与周围正常组织相比，肺癌组织中帮助肿瘤细胞逃逸的调节性CD4+T细胞(Tregs)的数量高，而靶向杀伤肿瘤细胞的CD8+CTL [<xref ref-type="bibr" rid="hanspub.44672-ref25">25</xref>] 的数量较低 [<xref ref-type="bibr" rid="hanspub.44672-ref26">26</xref>]。有研究表明，纤维蛋白原与肿瘤组织内血管内皮生长因子(VEGF)以及缺氧诱导因子-1α的表达密切相关，反应肿瘤的血管生成状况，不容忽视。IEF较高的患者有较高的淋巴细胞、中性粒细胞数量以及纤维蛋白原水平，较低的白蛋白水平以及淋巴细胞数量，这可能是IEF成为接受EGFR-TKI治疗IV期NSCLC患者预后因子的部分原因。</p><p>这项研究有一些局限性，首先是治疗前1~2周进行血液检查。检测指标可能会根据个人的身体状况变化。其次，本研究为小样本单中心非随机回顾性研究，可能会存在以选择偏倚为主的统计误差。IEF临界值无国际标准，ROC曲线由于利用曲线下面积，得出假阳性和假阴性都最小的一点，所以用于IEF的临界值确定中，相关国际标准，尚在讨论。</p></sec><sec id="s9"><title>基金项目</title><p>国自然项目基金支持：项目号grant No. 82003997 项目负责人：吴大鹏。</p></sec><sec id="s10"><title>文章引用</title><p>杨 雪,刘根利,李 玲,吴大鹏,王笑荷,陶凤英,袁胜利. 免疫环境因子IEF在EGFR-TKIs治疗的EGFR突变阳性晚期非小细胞肺癌中预后价值研究The Predictive Value of Immune Environment Factors (IEF) for the Prognosis of EGFR Mutations Positive Non-Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors (EGFR-TKIs)[J]. 临床医学进展, 2021, 11(08): 3553-3561. https://doi.org/10.12677/ACM.2021.118519</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.44672-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Arbour, K.C. and Riely, G.J. (2019) Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer A Review. JAMA—Journal of the American Medical Association, 322, 764-774. 
&lt;br&gt;https://doi.org/10.1001/jama.2019.11058</mixed-citation></ref><ref id="hanspub.44672-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Bartholomew, C., Eastlake, L., Dunn, P., et al. (2017) EGFR Targeted Therapy in Lung Cancer: An Evolving Story. Respiratory Medicine Case Reports, 20, 137-140.</mixed-citation></ref><ref id="hanspub.44672-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Maemondo, M. (2020) Potential of Combination Therapy in EGFR Mutated Lung Cancer. Annals of Translational Medicine, 8, 518. &lt;br&gt;https://doi.org/10.21037/atm.2020.03.76</mixed-citation></ref><ref id="hanspub.44672-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Ettinger, D.S., Wood, D.E., Aggarwal, C., et al. (2019) Non-Small Cell Lung Cancer, Version 1.2020 Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network, 17, 1464-1472. 
&lt;br&gt;https://doi.org/10.6004/jnccn.2019.0059</mixed-citation></ref><ref id="hanspub.44672-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Nemeth, T., Sperandio, M. and Mocsai, A. (2020) Neutrophils as Emerging Therapeutic Targets. Nature Reviews Drug Discovery, 19, 253-275. &lt;br&gt;https://doi.org/10.1038/s41573-019-0054-z</mixed-citation></ref><ref id="hanspub.44672-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Ren, W.H., Hou, J.F., Yang, C.G., et al. (2019) Extracellular Vesicles Secreted by Hypoxia Pre-Challenged Mesenchymal Stem Cells Promote Non-Small Cell Lung Cancer Cell Growth and Mobility as Well as Macrophage M2 Polarization via miR-21-5p Delivery. Journal of Experimental &amp; Clinical Cancer Research, 38, 62.</mixed-citation></ref><ref id="hanspub.44672-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Tanizaki, J., Haratani, K., Hayashi, H., et al. (2018) Peripheral Blood Biomarkers Associated with Clinical Outcome in Non-Small Cell Lung Cancer Patients Treated with Nivolumab. Journal of Thoracic Oncology, 13, 97-105. 
&lt;br&gt;https://doi.org/10.1016/j.jtho.2017.10.030</mixed-citation></ref><ref id="hanspub.44672-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Sheng, L., Luo, M., Sun, X., et al. (2013) Serum Fibrinogen Is an Independent Prognostic Factor in Operable Nonsmall Cell Lung Cancer. International Journal of Cancer, 133, 2720-2725. &lt;br&gt;https://doi.org/10.1002/ijc.28284</mixed-citation></ref><ref id="hanspub.44672-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Wang, H., Zhao, J., Zhang, M., et al. (2018) The Combination of Plasma Fibrinogen and Neutrophil Lymphocyte Ratio (F-NLR) Is a Predictive Factor in Patients with Resectable Non Small Cell Lung Cancer. Journal of Cellular Physiology, 233, 4216-4224. &lt;br&gt;https://doi.org/10.1002/jcp.26239</mixed-citation></ref><ref id="hanspub.44672-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Wang, M., Zhang, G., Zhang, Y., et al. (2020) Fibrinogen Alpha Chain Knockout Promotes Tumor Growth and Metastasis through Integrin-AKT Signaling Pathway in Lung Cancer. Molecular Cancer Research, 18, 943-954.</mixed-citation></ref><ref id="hanspub.44672-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Li, J., Wang, Y., Wu, Y., et al. (2021) Prognostic Value of Pretreatment Albumin to Globulin Ratio in Lung Cancer: A Meta-Analysis. Nutrition and Cancer, 73, 75-82. &lt;br&gt;https://doi.org/10.1080/01635581.2020.1737155</mixed-citation></ref><ref id="hanspub.44672-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Karageorgou, E. and Samanidou, V. (2014) Youden Test Application in Robustness Assays during Method Validation. Journal of Chromatography A, 1353, 131-139.</mixed-citation></ref><ref id="hanspub.44672-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Schisterman, E.F., Perkins, N.J., Liu, A., et al. (2005) Optimal Cut-Point and Its Corresponding Youden Index to Discriminate Individuals Using Pooled Blood Samples. Epidemiology, 16, 73-81.  
&lt;br&gt;https://doi.org/10.1097/01.ede.0000147512.81966.ba</mixed-citation></ref><ref id="hanspub.44672-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Chen, X., Zhang, L. and Liu, X. (2018) Association of Systemic Inflammation with Survival in EGFR Wild-Type Lung Cancer. Annals of Oncology, 29, IX155.</mixed-citation></ref><ref id="hanspub.44672-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Serresi, M., Gargiulo, G., Proost, N., et al. (2016) Polycomb Repressive Complex 2 Is a Barrier to KRAS-Driven Inflammation and Epithelial-Mesenchymal Transition in Non-Small-Cell Lung Cancer. Cancer Cell, 29, 17-31. 
&lt;br&gt;https://doi.org/10.1016/j.ccell.2015.12.006</mixed-citation></ref><ref id="hanspub.44672-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Shiels, M.S., Pfeiffer, R.M., Hildesheim, A., et al. (2013) Circulating Inflammation Markers and Prospective Risk for Lung Cancer. Journal of the National Cancer Institute, 105, 1871-1880. &lt;br&gt;https://doi.org/10.1093/jnci/djt309</mixed-citation></ref><ref id="hanspub.44672-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Amaral, S.R., Casal Moura, M., Carvalho, J., et al. (2019) Prognostic Significance of Neutrophil-To-Lymphocyte Ratio (NLR) and Platelet-To-Lymphocyte Ratio (PLR) in Non-Small Cell Lung Cancer (NSCLC) Treated with Immune Checkpoint Inhibitors. Annals of Oncology, 30, I3.</mixed-citation></ref><ref id="hanspub.44672-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Rapoport, B.L., Vorobiof, D.A., Langenhoven, L., et al. (2019) Prognostic Significance of Neutrophil/Lymphocyte ratio in Patients Undergoing Treatment with Nivolumab for Recurrent Non-Small Cell Lung Cancer. Annals of Oncology, 30, II61.</mixed-citation></ref><ref id="hanspub.44672-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Xiao, Y., Cong, M., Li, J., et al. (2021) Cathepsin C Promotes Breast Cancer Lung Metastasis by Modulating Neutrophil Infiltration and Neutrophil Extracellular Trap Formation. Cancer Cell, 39, 423-437.</mixed-citation></ref><ref id="hanspub.44672-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Choi, S.H., Kim, A.R., Nam, J.K., et al. (2018) Tumour-Vasculature Development via Endothelial-To-Mesenchymal Transition after Radiotherapy Controls CD44v6+ Cancer Cell and Macrophage Polarization. Nature Communications, 9, Article No. 5108. &lt;br&gt;https://doi.org/10.1038/s41467-018-07470-w</mixed-citation></ref><ref id="hanspub.44672-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Chen, Y.B., Song, Y.C., Du, W., et al. (2019) Tumor-Associated Macrophages: An Accomplice in Solid Tumor Progression. Journal of Biomedical Science, 26, 78.</mixed-citation></ref><ref id="hanspub.44672-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Ruffell, B. and Coussens, L.M. (2015) Macrophages and Therapeutic Resistance in Cancer. Cancer Cell, 27, 462-472. 
&lt;br&gt;https://doi.org/10.1016/j.ccell.2015.02.015</mixed-citation></ref><ref id="hanspub.44672-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Wang, J., Li, D., Cang, H., et al. (2019) Crosstalk between Cancer and Immune Cells: Role of Tumor-Associated Macrophages in the Tumor Microenvironment. Cancer Medicine, 8, 4709-4721. &lt;br&gt;https://doi.org/10.1002/cam4.2327</mixed-citation></ref><ref id="hanspub.44672-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Joshi, K., De Massy, M.R., Ismail, M., et al. (2019) Spatial Heterogeneity of the T Cell Receptor Repertoire Reflects the Mutational Landscape in Lung Cancer. Nature Medicine, 25, 1549-1559.  
&lt;br&gt;https://doi.org/10.1038/s41591-019-0592-2</mixed-citation></ref><ref id="hanspub.44672-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Lu, Y., Xue, J., Deng, T., et al. (2020) Safety and Feasibility of CRISPR-Edited T Cells in Patients with Refractory Non-Small-Cell Lung Cancer. Nature Medicine, 26, 732-740. &lt;br&gt;https://doi.org/10.1038/s41591-020-0840-5</mixed-citation></ref><ref id="hanspub.44672-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Inomata, M., Kado, T., Okazawa, S., et al. (2019) Peripheral PD1-Positive CD4 T-Lymphocyte Count Can Predict Progression-Free Survival in Patients With Non-Small Cell Lung Cancer Receiving Immune Checkpoint Inhibitor. Anticancer Research, 39, 6887-6893.</mixed-citation></ref></ref-list></back></article>